Feng Y - Search Results

1

An Improved ²¹¹At-Labeled Agent for PSMA-Targeted α-Therapy.

Mease RC, Kang CM, Kumar V, Banerjee SR, Minn I, Brummet M, Gabrielson KL, Feng Y, Park A, Kiess AP, Sgouros G, Vaidyanathan G, Zalutsky MR, Pomper MG. Mease RC, et al. Among authors: feng y. J Nucl Med. 2022 Feb;63(2):259-267. doi: 10.2967/jnumed.121.262098. Epub 2021 Jun 4. J Nucl Med. 2022. PMID: 34088772 Free PMC article.

2

Site-specific radioiodination of an anti-HER2 single domain antibody fragment with a residualizing prosthetic agent.

Feng Y, Zhou Z, McDougald D, Meshaw RL, Vaidyanathan G, Zalutsky MR. Feng Y, et al. Nucl Med Biol. 2021 Jan;92:171-183. doi: 10.1016/j.nucmedbio.2020.05.002. Epub 2020 May 12. Nucl Med Biol. 2021. PMID: 32448731 Free PMC article.

3

Production, purification and availability of ²¹¹At: Near term steps towards global access.

Feng Y, Zalutsky MR. Feng Y, et al. Nucl Med Biol. 2021 Sep-Oct;100-101:12-23. doi: 10.1016/j.nucmedbio.2021.05.007. Epub 2021 Jun 10. Nucl Med Biol. 2021. PMID: 34144505 Free PMC article. Review.

4

Gold Nanostars: A Novel Platform for Developing ²¹¹At-Labeled Agents for Targeted Alpha-Particle Therapy.

Liu Y, Zhou Z, Feng Y, Zhao XG, Vaidyanathan G, Zalutsky MR, Vo-Dinh T. Liu Y, et al. Among authors: feng y. Int J Nanomedicine. 2021 Oct 28;16:7297-7305. doi: 10.2147/IJN.S327577. eCollection 2021. Int J Nanomedicine. 2021. PMID: 34737567 Free PMC article.

5

Evaluation of an ¹³¹I-labeled HER2-specific single domain antibody fragment for the radiopharmaceutical therapy of HER2-expressing cancers.

Feng Y, Meshaw R, McDougald D, Zhou Z, Zhao XG, Jannetti SA, Reiman RE, Pippen E, Marjoram R, Schaal JL, Vaidyanathan G, Zalutsky MR. Feng Y, et al. Sci Rep. 2022 Feb 22;12(1):3020. doi: 10.1038/s41598-022-07006-9. Sci Rep. 2022. PMID: 35194100 Free PMC article.

6

Effective Treatment of Human Breast Carcinoma Xenografts with Single-Dose ²¹¹At-Labeled Anti-HER2 Single-Domain Antibody Fragment.

Feng Y, Meshaw R, Zhao XG, Jannetti S, Vaidyanathan G, Zalutsky MR. Feng Y, et al. J Nucl Med. 2023 Jan;64(1):124-130. doi: 10.2967/jnumed.122.264071. Epub 2022 May 26. J Nucl Med. 2023. PMID: 35618478 Free PMC article.

7

Site-Specific Radiohalogenation of a HER2-Targeted Single-Domain Antibody Fragment Using a Novel Residualizing Prosthetic Agent.

Feng Y, Sarrett SM, Meshaw RL, Vaidyanathan G, Cornejo MA, Zeglis BM, Zalutsky MR. Feng Y, et al. J Med Chem. 2022 Nov 24;65(22):15358-15373. doi: 10.1021/acs.jmedchem.2c01331. Epub 2022 Nov 11. J Med Chem. 2022. PMID: 36368007 Free PMC article.

8

A third generation PSMA-targeted agent [²¹¹At]YF2: Synthesis and in vivo evaluation.

Feng Y, Meshaw RL, Finch SW, Zheng Y, Minn I, Vaidyanathan G, Pomper MG, Zalutsky MR. Feng Y, et al. Nucl Med Biol. 2024 Jul-Aug;134-135:108916. doi: 10.1016/j.nucmedbio.2024.108916. Epub 2024 May 1. Nucl Med Biol. 2024. PMID: 38703587

9

PSMA-reactive NB7 single domain antibody fragment: A potential scaffold for developing prostate cancer theranostics.

Huynh TT, Feng Y, Meshaw R, Zhao XG, Rosenfeld L, Vaidyanathan G, Papo N, Zalutsky MR. Huynh TT, et al. Among authors: feng y. Nucl Med Biol. 2024 Jul-Aug;134-135:108913. doi: 10.1016/j.nucmedbio.2024.108913. Epub 2024 Apr 25. Nucl Med Biol. 2024. PMID: 38703588

10

Pore-Scale Gas Storage Mechanisms, Characteristics, and Influencing Factors in Water-Bearing Shale: Insights from Molecular Dynamics Simulations.

Zhang X, Dang W, Zhang Q, Nie H, Chen S, Feng Y, Shangguan L, Qiu Z. Zhang X, et al. Among authors: feng y. ACS Omega. 2024 Nov 14;9(47):47005-47022. doi: 10.1021/acsomega.4c06869. eCollection 2024 Nov 26. ACS Omega. 2024. PMID: 39619537 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

26,392 results

Search Page

Filters